Dr. Francesco Piraino, Scientist Bioengineer - Quanterix, Inc,
"Monitoring Health and Disease Progression with Utrasensitive Biomarker Analysis"
Quanterix Simoa™ technology detects proteins with 1000]fold higher sensitivity than traditional immunoassays
ltrasensitive detection is enabling the identification of more informative biomarkers requiring less invasive and less expensive testing procedures
to improve our understanding of neurodegenerative disease.
Simoa assays are currently applied across various therapeutic areas including neurology, oncology, cardiology, inflammation and infectious
disease to detect biomarkers in a variety of sample matrices.
Quanterix cytokine assays lead the field with respect to precision, disease correlation and detection of endogenous analytes.Quanterix offers a large menu of commercially available assays, an open instrument platform for developing homebrew assays, and assay testing services.
BIO: Francesco Piraino is a research scientist at the Swiss Federal Institute of Technology in Lausanne (Switzerland). He uses microscale technologies to develop next-generation microfluidic diagnostics platforms. Following his graduate studies in Biomedical Engineering at Politecnico di Milano (Italy) and at Harvard-MIT Division of Health Science & Technology (USA), he joined the Broad Institute of MIT and Harvard (USA) to develop devices for single-cell genomics. Dr. Piraino is a trained bioengineer who has also attended programs at the Universitat de Barcelona (Spain), the City
College of the City University of New York (USA), and the Massachusetts Institute of Technology (USA). His work aims to solve problems at the intersection of biomedical engineering and medicine.
Host: Clinical Neuroimmunology, email@example.com